99 results about "In vitro in vivo" patented technology

The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.

The invention provides a human brain glioma cell line and an establishing method and application thereof. The human brain glioma cell line is preserved in China Center for Typical Culture Collection with an accession number of CCTCC No. C201115. The human brain glioma cell line is established by subjecting brain glioma cells originated from a clinic specimen to primary culture and subculture, can be directly used for in vitro drug screening or generation of human brain glioma in mammals and is used for establishing a human brain glioma animal model and screening candidate drugs used for treating human brain glioma. The human brain glioma cell line has stable properties, can realize stable multiple passages and maintain stable properties even after in vitro passage to the 50th generation; pathogenesis of human brain glioma, drug susceptibility, transitivity and other related characteristics can be analyzed in vitro and in vivo, so two correlated in-vitro and in-vivo anti-brain glioma drug screening platforms can be established, and novel experimental materials closer to clinic oncobiological characteristics are provided for research on human brain glioma.

The invention provides a family of fluorescent compounds. The compounds are substituted silaxanthenium compounds that can be chemically linked to one or more biomolecules, such as a protein, nucleic acid, and therapeutic small molecule. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. The dyes are particularly useful for in vitro, in vivo and ex vivo imaging applications.

This invention relates to a method for producing recombinant human kallikrein-1 (r-HK1) with Pichia pastoris. This invention also describes molecular weight, isoelectric point, and sugar content and glycosyl modification of r-HK1. It is proven by in vivo and in vitro activity experiments that r-HK1 can be used to treat and prevent cerebral infraction.

The invention discloses an anti-cancer drug nanocapsule with near-infrared photothermal response and a preparation method thereof. The near-infrared photothermal characteristic of Cu1.75S NPs and the pH and temperature sensitivity of p(NIPAM-MAA) are combined, the surfaces of Cu2-xS nanoparticles with the near-infrared photothermal effect are covered with a layer of macromolecules sensitive to pH and temperature through in-situ polymerization, the thickness of the outer layer of macromolecules of the nanocapsule can be changed by adjusting the dosage of cross-linking agent bisacrylamide, then an anti-cancer drug is loaded, and leakage hardly occurs under normal physiological conditions (pH 7.4, 37 DEG C) without illumination. The nanocapsule has long-term stable ultrahigh photothermal conversion efficiency, high drug loading capacity (40%) and good biocompatibility. Furthermore, in-vitro and in-vivo photothermal chemotherapy results show that the nanocapsule can be used for long-distance non-destructive photothermal drug delivery and long-term continuous photothermal therapy and photothermal-controlled chemotherapy.

The present invention provides novel biophotonic sensors that have molecular recognition with high sensitivity for target molecules. In one embodiment, the biophotonic sensors have capture moieties with high specificity for molecules of interest (target molecules) and biophotonic conjugates. The biophotonic conjugates exhibit a characteristic photonic activity only when a target molecule is bound. This characteristic photonic activity may include, but is not limited to, either a qualitative response or a measurable change in photonic characteristics upon interaction of the sensors with the target molecules. Methods are also provided for use of the biophotonic sensors to detect molecules of interest either in vitro, in vivo, or in situ.

The invention relates to a kueide mycin which is a novel derivative of geldanamycin. According to the anticancer activity experiment, kueide mycin has in both vitro and vivo antitumor activities. The kueide mycin has the in vitro activity characteristics of inhibiting tumor cell proliferation, inducing the tumor cell apoptosis, reducing related target proteins of Hsp 90 in the tumor cells, as well as inhibiting the tumor cell migration, and has in vivo antitumor activity characteristics of notably reducing poisonousness compared to the geldanamycin. The kueide mycin can obviously inhibit the growth of solid tumor of a nude mouse model of Human breast carcinoma xenografts after being injected in a peritoneal cavity and is expected to be developed into a clinical effective antitumor drug.

The invention discloses a three-dimensional tissue-like body of composite cells. By grafting small molecule compounds containing double bonds onto gelatin molecules with excellent biocompatibility tobuild gelatin DB-Gel modified by groups containing double bonds, a gelatin DB-Gel aqueous solution of a certain concentration is mixed with living cell (such as parathyroid gland cells) suspension, and through ultraviolet light curing, the three-dimensional tissue-like body of the composite cells is obtained. In the process of building the tissue-like body, DB-Gel is fully utilized as photo-polymerized hydrogel and has good bioactivity; by directly mixing the gelatin DB-Gel and the cells in a liquid state, the cells can be completely and uniformly dispersed in space, a three-dimensional growing environment closer to the internal environment is built for the cells, the efficiency of interaction between the cells and the external environment is improved in a three-dimensional cell culturingprocess, and compared with cells cultured in two dimensions, maintenance of cell forms and activity are both improved. A preparation method of the three-dimensional tissue-like body of the composite cells is simple, rapid and low in both equipment requirement and cost, and has great potential in internal and external research.

The invention discloses a skeletal muscle whole organ acellular matrix, its derived medical products, such as particles, fluidized compositions, gels and active peptides, and preparation and use methods of the matrix and the medical products. The skeletal muscle whole organ acellular matrix completely reserves the skeletal muscle three-dimensional parallelly-arrayed skeletal muscle basement membrane ultra-structure, the vascular matrix network and muscle-tendon joints, reserves large amounts of bioactive components comprising growth factors, hyaluronic acid, glycosaminoglycan, laminins and the like, is highly affinity to muscle-derived stem cells, has the advantages of certain mechanical strength and toughness, thorough decellularization, no obvious immunological rejection, and no ethical or moral issues, and is a skeletal muscle regeneration scaffold and platform having the most advantages reported so far. The prepared skeletal muscle whole organ acellular matrix and its derived medical products can be used for the in-vitro and in-vivo construction and regeneration of the skeletal muscles, are suitable for restoring the skeletal muscle coloboma of various positions in various ranges, and are expected to solve the large-range skeletal muscle coloboma restoration and muscle regeneration problems.

The invention discloses human glioma primary cells and an in-vitro isolation and culture method and an application thereof. The cells are named as a low-grade human glioma primary cell XHLG-07 and a high-grade human glioma primary cell XHHG-02 and have the preservation numbers of CCTCC NO:C2018256 and CCTCC NO:C2018215 respectively. The isolation and culture method comprises the steps: acquiring aglioma tissue excised after operation in clinic in vitro, removing blood vessels in the tissue and an adipose tissue by anatomical tweezers, digesting by collagenase/pancreatin, filtering, carrying out low-speed centrifugation to obtain a cell precipitate, carrying out lysis of erythrocytes with an erythrocyte lysis solution, resuspending cells in a DF31 complete culture medium and carrying out inoculation culture. The isolation method can be used for acquiring WHO glioma primary cells with different grades. The obtained cells can be used for analyzing pathogenesis, drug sensitivity and metastasis of human brain gliomas with different grades in vitro and in vivo, and provide research materials more similar to the biological characteristics of clinical tumors for the study of human brain gliomas with different grades.

A oligonucleotide probe containing specific probe and switch sequences for in vitro, in vivo and intracellular detection and identification of target sequences and molecules. Methods of using such probes for the detection of target sequences and molecules in various cells and tissues as well as a variety of biological samples and fluids. Methods of using such probes in non-clinical areas, such as agriculture.

The invention provides a piribedil hydrophilic gel membrane controlled and sustained release preparation and a preparation method thereof. The piribedil sustained release tablet comprises a hydrophilic gel framework material, a filling agent, a lubricating agent, an adhesive and a sustained release coating material. The piribedil hydrophilic gel membrane controlled and sustained sustained release preparation is prepared through the following steps that 1, main drug piribedil is micronized; 2, the micronized main drug piribedil and the filling agent are evenly mixed, a proper amount of the adhesive is added, and pelletizing, drying and grain finishing are carried out; 3, the dry particles in the step 2 and the hydrophilic gel framework material are evenly mixed, then the lubricating agent is added, and even mixing and tabletting are carried out; 4, tablet cores in the step 3 are placed in a coating pan, the sustained release coating material is subjected to coating, and the hydrophilic gel membrane controlled and sustained sustained release tablet is obtained. The hydrophilic gel framework material and the sustained release coating material are adopted in the piribedil sustained release tablet, release of piribedil is delayed, release of the drug is more stable, and the drug effect is improved. The compliance of a patient is improved, and meanwhile good in vitro-in vivo correlation is achieved.

The present invention is that on the basis of rifampicin and isoniazide micro pill preparation of patent No. 03101211.6, the release status of the micro pill inside solution in specific conditions and the human body's pharmacokinetic characteristic of the micro pill in human body as the tested object are measured according to the method of Chinese pharmacopoeia.

The invention relates to the field of biopharmaceutics, in particular to a liposome preparation for anticoagulant thrombolytic difunctional fusion protein, namely anticoagulant thrombolytic difunctional fusion protein of 12 peptides of hirudin and reteplase (HV12p-rPA) and a preparation method thereof. The anticoagulant thrombolytic difunctional fusion protein (HV12p-rPA) constructed in the laboratory has the dual effects of anticoagulation and thrombolysis by structural identification, expression, chromatography renaturation, purification and extracorporal and intracorporal pharmacodynamic experiments. In the preparation method, the liposome preparation is prepared from the anticoagulant thrombolytic difunctional fusion protein serving as a raw material, and a liposome is prepared by an optimized membrane dispersion-probe ultrasonic method; and the optimized membrane dispersion-probe ultrasonic method is characterized in that a prescription which is most suitable for improving the envelop rate of the HV12p-rPA liposome is selected by taking a ratio of phospholipid to cholesterol, the concentration of protein medicaments, the volume of buffer solution and water-bath ultrasonic time as influence factors, and the grain diameter of the HV12p-rPA liposome is reduced and homogenized further by probe ultrasonic, so that the HV12p-rPA liposome of which the grain diameter is between 140 and 145 nanometers and which is used for intravenous injection is prepared. By the preparation method, the envelop rate of the prepared HV12p-rPA liposome is over 90 percent, and extracorporal thrombolytic activity and extracorporal anticoagulant activity are 23,810 international unit (IU) .mg<1> and 414 antithrombin unit (ATU) .mg<1> respectively.

The invention discloses a human esophageal carcinoma cell line and application thereof. The human esophageal carcinoma cell line is preserved in China Center For Type Culture Collection with a preservation number of CCTCC NO:C201661. Under the premise of retaining the main clinical biological features, the human esophageal carcinoma cell line has the characteristics of high tumor formation rate, short incubation period, good homogeneity and the like, enriches the human esophageal carcinoma cell library, provides powerful scientific research material for study of China population genetic background, and also provides a new experimental material for new drug preclinical study of in vivo and in vitro experiments.

The invention belongs to the technical field of medical chemistry, and particularly relates to amino lipid as well as a preparation method and application thereof. The invention provides an ionizable amino lipid represented by a general formula (I) or a pharmaceutically acceptable salt thereof. The amino lipid can be used for delivering nucleic acid and small molecule drugs. The amino lipid compound has two ester bonds, so that the lysosomal escape capability of ionizable amino lipid is remarkably enhanced, release of delivery targets such as target drugs or genes is facilitated, the delivery efficiency is further improved, and the amino lipid compound shows excellent capability of delivering nucleic acid into cells in in-vitro and in-vivo delivery studies.

The invention relates to a bleomycin derivative or pharmaceutically acceptable salt. The derivative has a structure as shown in the specification, wherein R=-NH-(CH=CH)n-C(NH2)=NH; and n is 0, 1, 2, 3 or 4. The bleomycin derivative is a Group B derivative of bleomycin and has an anti-tumor effect. Especially the terminal R group and bithiazole can generate conjugative effect, which is helpful for chelation between the derivative and 111 indium to form a chelate. As tumor cells are easier to absorb the bleomycin derivative than normal cells, 111 indium can be carried into tumor cells with small use amount of the bleomycin derivative after the bleomycin derivative and 111 indium are chelated to form the chelate; and 111 indium has short half-life and moderate radioactive activity and can generate a good in vitro-in vivo anti-tumor effect and especially has a good effect on head and neck neoplasms.

The invention provides a method for detecting red blood cell phagocytosis based on 18F-FDG, and provides a new method for detecting phagocytic rate of red blood cells. When 18F-FDG is absorbed into the red blood cells, the surface molecule state of the red blood cells is not changed, which is more able to reflect the phagocytosis condition of the red blood cells under real conditions. The invention also provides a method for detecting the distribution of the red blood cells in a body based on 18F-FDG, which can simultaneously observe the phagocytosis of labeled red blood cells in the body andout of the body, so as to determine whether the blood transfusion is effective or not; therefore, a direct evidence for assisting diagnosis of useless red blood cell transfusion is provided.